The patient experience: Treatment with BCMA-directed therapies in relapsed MM

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat chaired a panel discussion featuring patient representative Lynn Williams, alongside faculty members Fredrik Schjesvold and Hang Quach, on real-world experience with belantamab mafodotin in multiple myeloma (MM). In this discussion, Williams shares her experience of long-term treatment with belantamab mafodotin, including treatment burden, adverse events, and impact on quality of life. The panel explores variability in patient experiences, strategies for managing ocular toxicity, and the role of dose modification and treatment scheduling in optimizing outcomes. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. Hosted on Acast. See acast.com/privacy for more information.